Oral LD50 (rat): 306 mg/kg; Oral LD50 (mice): 130 mg/kg; Oral LD50 (guinea pig): 198 mg/kg Registry of Toxic Effects of Chemical Substances. Ed. D. Sweet, US Dept. of Health & Human Services: Cincinatti, 2010.
Also a mild reproductive toxin to women of childbearing age.
A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ivabradine | Ivabradine may increase the QTc-prolonging activities of Chlorpheniramine. |
| Buprenorphine | Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorpheniramine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorpheniramine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorpheniramine. |
| Magnesium sulfate | The therapeutic efficacy of Chlorpheniramine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Chlorpheniramine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorpheniramine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorpheniramine. |
| Orphenadrine | Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorpheniramine. |
| Pramipexole | Chlorpheniramine may increase the sedative activities of Pramipexole. |
| Ropinirole | Chlorpheniramine may increase the sedative activities of Ropinirole. |
| Rotigotine | Chlorpheniramine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorpheniramine. |
| Sodium oxybate | Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorpheniramine. |
| Thalidomide | Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Benzylpenicilloyl polylysine | Chlorpheniramine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Chlorpheniramine. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorpheniramine. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Chlorpheniramine. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorpheniramine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Chlorpheniramine. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Chlorpheniramine. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Chlorpheniramine. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Phenindione. |
| Coumarin | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Coumarin. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Tioclomarol. |
| Warfarin | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with 4-hydroxycoumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Diphenadione. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with (S)-Warfarin. |
| Mirabegron | The serum concentration of Chlorpheniramine can be increased when it is combined with Mirabegron. |
| Tedizolid phosphate | The risk or severity of serotonin syndrome can be increased when Tedizolid phosphate is combined with Chlorpheniramine. |
| Phenytoin | The serum concentration of Phenytoin can be increased when it is combined with Chlorpheniramine. |
| Fosphenytoin | The serum concentration of Fosphenytoin can be increased when it is combined with Chlorpheniramine. |
| Mirtazapine | Chlorpheniramine may increase the serotonergic activities of Mirtazapine. |
| Ethanol | Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorpheniramine. |
| Sertraline | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Sibutramine. |
| Zimelidine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Chlorpheniramine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Chlorpheniramine is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Indalpine. |
| Alaproclate | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Alaproclate. |
| Amphetamine | Amphetamine may decrease the sedative activities of Chlorpheniramine. |
| Phentermine | Phentermine may decrease the sedative activities of Chlorpheniramine. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Chlorpheniramine. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Chlorpheniramine. |
| Lisdexamfetamine | The risk or severity of serotonin syndrome can be increased when Chlorpheniramine is combined with Lisdexamfetamine. |
| Mephentermine | Mephentermine may decrease the sedative activities of Chlorpheniramine. |
| MMDA | MMDA may decrease the sedative activities of Chlorpheniramine. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Chlorpheniramine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Chlorpheniramine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Chlorpheniramine. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Chlorpheniramine. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Chlorpheniramine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Chlorpheniramine. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Chlorpheniramine. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Chlorpheniramine. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Chlorpheniramine. |
| Ritobegron | Ritobegron may decrease the sedative activities of Chlorpheniramine. |
| Mephedrone | Mephedrone may decrease the sedative activities of Chlorpheniramine. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Chlorpheniramine. |
| Gepefrine | Gepefrine may decrease the sedative activities of Chlorpheniramine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Chlorpheniramine. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Chlorpheniramine. |
| Methylene blue | Chlorpheniramine may increase the serotonergic activities of Methylene blue. |
| Trospium | The metabolism of Chlorpheniramine can be decreased when combined with Trospium. |
| Doxepin | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Doxepin. |
| Zopiclone | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Zopiclone. |
| Thiethylperazine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Thiethylperazine. |
| Triflupromazine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Triflupromazine. |
| Fluphenazine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Fluphenazine. |
| Trifluoperazine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Trifluoperazine. |
| Acetophenazine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Acetophenazine. |
| Periciazine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Periciazine. |
| Acepromazine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Acepromazine. |
| Molindone | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Molindone. |
| Thioproperazine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Thioproperazine. |
| Osanetant | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Osanetant. |
| Bifeprunox | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Bifeprunox. |
| BL-1020 | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with BL-1020. |